Issue 15 - Apr 13, 2018
  • Sharpless: Expect a big boost to NCI’s RPG pool

    NCI’s Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.

    The increase is made possible by a $3 billion raise to NIH’s budget that translates into $275 million in new money for the institute in fiscal year 2018.

  • Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

    A whistleblower lawsuit alleges that McKesson Corp. had been repackaging cancer drugs and charging the federal and state governments for “overfill,” extra drug that is routinely put into vials by manufacturers.

  • In Brief

    • Gradishar named chief of hematology and Oncology at Northwestern
    • Cole named chief of pediatric hematology/oncology at Rutgers
    • ACS CAN report examines patient barriers to cancer clinical trial enrollment
    • Woodcock, Shaw and Conway-Welch receive awards from Society for Women’s Health Research
    • Billings appointed chief medical officer at Natera
  • Funding Opportunities

    DOD Ovarian Cancer Research Program Publishes funding opportunities

    FY18 OCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

  • TCCL Logo

  • Trials and Tribulations

    Sales Revenues at the Potential Expense of Patient Safety: The Example of You&i TM

    Ibrutinib is a selective and irreversible inhibitor of Bruton’s tyrosine kinase (BTK) that entered phase 1 clinical trials in 2009 based on preclinical efficacy in models of B-cell malignancy and autoimmune disease.[1, 2] The initial phase 1 trial showed clear efficacy in a number of lymphoid malignancies at doses as low as 1.25 mg/kg/d. Furthermore, full receptor occupancy was demonstrated at 2.5 mg/kg/d. Despite these pharmacological and early clinical findings, development of ibrutinib continued at doses of 420 mg qd and 560 mg qd, levels 3-4 fold higher than suggested by the pharmacological data. In addition, the absorption of ibrutinib is enhanced by administration of food, which may explain why even the lowest dose showed efficacy in some patients.

  • Clinical Roundup

    • NCI study revises molecular classification for most common type of lymphoma
    • Updated ASTRO guideline for lung radiation recommends concurrent chemotherapy for some stage III patients
    • Keytruda monotherapy meets OS endpoint in phase III trial
    • Epacadostat plus Keytruda don’t meet PFS endpoint in phase III study in metastatic melanoma
    • Roswell Park, Ohio State researchers identify genes linked to blood and marrow transplant outcomes
  • Drugs and Targets

    • Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • FDA finalizes guidances to accelerate development of Next Gen sequencing
    • Karyopharm’s Selinexor receive FDA Fast Track designation
    • MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab
Issue 14 - Apr 6, 2018
Issue 13 - Mar 30, 2018
  • New players, new strategies, new resolve raise NIH budget to new level

    On March 14, beneath the soaring ceiling of the Andrew W. Mellon Auditorium, Rep. Nancy Pelosi (D-CA) faced a constellation of round tables at the Research!America 2018 Advocacy Awards Dinner.

  • Duke faces tightened NIH grant oversight over handling of past scientific misconduct

    NIH has imposed tighter financial controls on researchers at Duke University, citing “ongoing issues” related to management of grants.

  • Conversation with the Cancer Letter

    University of Michigan gets $150 million to recruit cancer researchers, fund research

    Richard and Susan Rogel gave $150 million to the University of Michigan Comprehensive Cancer Center, which will now be known as the Rogel Cancer Center.

  • AACR announces scientific award winners, new board of directors

    The following cancer researchers and clinicians will be recognized for their scientific achievements during the American Association for Cancer Research annual meeting.

  • An Appreciation

    James Holland, an oncology pioneer, dies at 92

    James Holland became a doctor thanks to what he calls “a series of fortunate mistakes.” The son of a prominent lawyer in Morristown, New Jersey, Holland was raised to go into law, too. But that changed when he took a course in biology at Princeton University and became enthralled with seeing cells under a microscope.

  • In Brief

    • Society of Surgical Oncology gives service award to Wolmark and Fisher
    • NCCN honors contributors to the Improvement of global cancer care
    • City of Hope and Fivepoint partner to bring outpatient center to Orange County
    • Thomas Gallo named ACCC President 2018-2019
    • ONS elects board of directors
    • Cohen joins department of radiation oncology at Fox Chase
  • Funding Opportunities

    DOD publishes funding opportunities for breast and prostate cancer programs

    AACR, AstraZeneca form training partnership

    The American Association for Cancer Research and AstraZeneca formed a partnership to help foster the next generation of cancer research scientists and stimulate innovative research in the areas of DNA Damage Response in cancer and Immuno-Oncology.

  • TCCL Logo

  • Clinical Roundup

    • Sorafenib improves PFS in rare sarcomas, NIH-funded study shows
    • Zejula plus Keytruda shows activity in refractory ovarian cancer
    • Retrospective analysis identifies predictors of dose modification for niraparib
  • Drugs and Targets

    • FDA gives accelerated approval for Blincyto for ALL patients with minimal residual disease
    • Enfortumab vedotin gets breakthrough designation in urothelial cancer
    • FDA approves changes on Hologic’s 3Dimensions Mammography System
    • FDA accepts application for Opdivo plus Yervoy for MSI-H or dMMR metastatic colorectal cancer for priority review
  • CTEP Protocols

    NCI Trials for March

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.